Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Reckitt Benckiser Group Plc (RB.) Ord 10p

Sell:6,070.00p Buy:6,074.00p 0 Change: No change
FTSE 100:0.85%
Market closed Prices as at close on 23 January 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:6,070.00p
Buy:6,074.00p
Change: No change
Market closed Prices as at close on 23 January 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:6,070.00p
Buy:6,074.00p
Change: No change
Market closed Prices as at close on 23 January 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

HL comment (22 October 2019)

Reckitt Benckiser has reported modest like-for-like (LFL) sales growth of 1.6% in its third quarter. That's half of what the market was expecting, with particular problems in the Health division.

Reckitt cut full year LFL growth targets again to 0-2%, down from 2-3% at the half year, and operating profits margins are also expected to shrink.

The shares fell 4.7% following the announcement.

View the latest Reckitt Benckiser share price and how to deal

Our View

Reckitt is a consumer goods group that makes household products from Nurofen to Dettol.

The traditional core of the business has generated reliable cash flows, driven by a diverse customer base buying small, everyday items. Added to that, a tried and tested formula of marketing and product innovation has helped sales, profits and dividends rise over the years.

But RB has strayed from its well-trodden path more recently. The $18bn acquisition of Mead Johnson (MJN), a baby formula specialist, raised eyebrows back in 2017. It marked entry into unfamiliar markets and unfamiliar products. A string of operational issues has weighed on margins, and demand for MJN baby formula in China isn't flying.

Unfortunately the disease seems to have spread to the broader Health business. It's growing slower than its wider market, thanks in part to greater caution from its retail partners, but price competition is heating up too. It's far too early to diagnose a crisis, but we worry Reckitt's brands may be losing some of their pulling power.

There have been other problems too. The sale of faulty products in Korea up to 2011 led to serious injury and the death of a number of people, and the number of compensation claimants continues to rise.

Fortunately there are some brighter spots. The settlement for Reckitt's past sale of opioid addiction treatments has finally been put to bed. The $1.4bn price tag was higher than some expected, but the group had already warned its original provision would likely need to be significantly increased. It means incoming CEO, Laxman Narasimhan, has one less thing to worry about.

We think near-term fortunes rely on MJN, and the group's ability to stabilise margins. Other news that could move the dial includes if Narasimhan decides to split the business into two. We expect he will want to have his feet under the table for a little while before making any decisions, but investors will inevitably be watching this space.

The shares currently trade on 16.6 times expected earnings, a touch above the longer-term average, and offer a prospective yield of 3%.

Register for updates on Reckitt Benckiser

Third Quarter Trading Statement

Revenue growth in the quarter reflects 3% growth in prices and product mix, with overall volume actually falling 1%.

The Health segment (60.9% of revenues) recorded a small slowdown in LFL sales of -0.3%. That was led by North America where LFL sales fell -12.3%. Infant Child Nutrition was the only major Health segment to report positive sales growth, however even here the group's losing market share in the key Chinese region. Durex and Dettol, meanwhile, returned to growth but remain below their historic run rates.

Hygiene Home offset the struggling Health segment, with LFL revenue growing 4.5%. Although all markets delivered a positive performance Developing Markets led the charge with 11.3% LFL growth. This was underpinned by strong performances from Harpic in India and Finish in China.

Reckitt's financial position did not change materially during the quarter. The group's paid $1.2bn of its $1.4bn Indivior related settlement, with the balance due in Q4.

Find out more about Reckitt Benckiser shares including how to invest

Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by Thomson Reuters. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.

This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.


Previous Reckitt Benckiser Group Plc updates

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.